Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
3.560
-0.200 (-5.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
23
24
Next >
Where Recursion Pharmaceuticals Stands With Analysts
↗
February 06, 2025
Via
Benzinga
Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
↗
February 06, 2025
Via
Benzinga
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
February 05, 2025
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Monster Stocks to Hold for the Next 10 Years
↗
February 01, 2025
A handful of companies are in the right place at the right time with the right product or service.
Via
The Motley Fool
How Is The Market Feeling About Recursion Pharmaceuticals?
↗
January 30, 2025
Via
Benzinga
Is Recursion Pharmaceuticals Stock a Buy?
↗
January 17, 2025
Via
The Motley Fool
AI Pharma: 2 Paths to AI-Powered Drug Investment
January 28, 2025
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
Via
MarketBeat
Topics
Artificial Intelligence
Nvidia-Backed Recursion Pharma Hits 3-Week High, Sparks Retail Buzz Amid Broader AI Hype
↗
January 22, 2025
The AI chipmaker’s $50 million investment in Recursion, unveiled in 2023 to support AI-driven drug discovery, has been a key driver of investor interest.
Via
Stocktwits
Topics
Artificial Intelligence
Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday
↗
January 22, 2025
Via
Benzinga
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
↗
January 21, 2025
Via
The Motley Fool
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
↗
December 21, 2024
Via
The Motley Fool
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
↗
January 18, 2025
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,...
Via
Talk Markets
Topics
Artificial Intelligence
Stocks / Equities
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
↗
January 11, 2025
Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT.
Via
Benzinga
Topics
Workforce
AI Drug Discovery Stocks: Recursion Pharmaceuticals Has A Long Road Ahead
↗
January 07, 2025
Among the various use-cases for AI, healthcare has been one of the interesting ones. Recursion Pharmaceuticals (RXRX) is one such notable player in the industry that has successfully leveraged AI in...
Via
Talk Markets
Topics
Artificial Intelligence
Stocks / Equities
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
January 07, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
January 06, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
↗
January 04, 2025
On Friday, Cathie Wood-led Ark Invest made significant trades involving PLTR, ARKB, and QSI. The PLTR trade sold shares worth $1.6 million, aligning with Ark's trend of reducing their position in the...
Via
Benzinga
Topics
Artificial Intelligence
ETFs
Nio, Unity Software And Other Big Stocks Moving Higher On Thursday
↗
January 02, 2025
Via
Benzinga
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
↗
December 21, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
December 20, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
↗
December 11, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
December 10, 2024
Via
Benzinga
What's Going On With Recursion Pharmaceuticals Stock?
↗
December 10, 2024
Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special...
Via
Benzinga
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
December 09, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
An Investor's Guide to the Artificial Intelligence (AI) Value Chain
↗
December 09, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday
↗
December 06, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
December 04, 2024
Via
Benzinga
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
December 04, 2024
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Berkshire Hathaway Isn't the Only Publicly Traded Company That Buys Stocks. These 3 Tech Giants Also Have Stock Portfolios.
↗
December 04, 2024
Via
The Motley Fool
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
December 03, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
